Table 2.

Differences in overall survival associated with immunotherapy in sex by subgroups.

		Participants, no.		Pooled HR (95% CI) for ICI vs. controlled therapies		Test for difference
Variable	Studies, no.	Male	Female	Male	Female	P value
Overall	18	8881	4430	0.77 (0.72, 0.82)	0.77 (0.67, 0.87)	0.955
Line of therapy
First	11	5460	2748	0.78 (0.72, 0.86)	0.74 (0.61, 0.89)	0.596
Subsequent	7	3421	1682	0.75 (0.69, 0.82)	0.80 (0.67, 0.96)	0.571
Intervention therapy
ICI alone	11	5128	2717	0.74 (0.68, 0.80)	0.82 (0.73, 0.92)	0.13
ICI combined with non-ICI	7	3753	1713	0.83 (0.76, 0.90)	0.68 (0.51, 0.91)	0.201
Pathologic types
Squamous	4	1855	408	0.76 (0.63, 0.93)	0.73 (0.46, 1.17)	0.886
Nonsquamous	5	2425	1605	0.80 (0.72, 0.89)	0.67 (0.51, 0.89)	0.252

Abbreviations: HR = hazard ratio; ICI = immune checkpoint inhibitor.